Ramana Kuchibhatla - Minerva Neurosciences Senior Development

All Insiders . USA . 
Stock . Minerva Neurosciences . Stakeholders . Insider . Ramana Kuchibhatla
NERV Stock  USD 2.26  0.02  0.89%   

Executive

Ramana Kuchibhatla is Senior Development of Minerva Neurosciences
Address 1500 District Avenue, Burlington, MA, United States, 01803
Phone617 600 7373
Webhttps://www.minervaneurosciences.com

Minerva Neurosciences Management Efficiency

The company has return on total asset (ROA) of (0.2891) % which means that it has lost $0.2891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.7509) %, meaning that it created substantial loss on money invested by shareholders. Minerva Neurosciences' management efficiency ratios could be used to measure how well Minerva Neurosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to climb to 1.11 in 2024, whereas Return On Tangible Assets are likely to drop (0.75) in 2024. At this time, Minerva Neurosciences' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to climb to about 52.9 M in 2024, whereas Other Assets are likely to drop slightly above 1.3 M in 2024.
Minerva Neurosciences currently holds 82.02 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Minerva Neurosciences has a current ratio of 20.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Minerva Neurosciences' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Shelly PintoAlx Oncology Holdings
47
Daryn LewisWave Life Sciences
N/A
HsiuChiung YangWave Life Sciences
N/A
David JonesEyepoint Pharmaceuticals
56
Bo KaraMereo BioPharma Group
N/A
Pablo MDKodiak Sciences
N/A
Sunil PharmDAnnexon
N/A
Shelly CPAAlx Oncology Holdings
48
Kiran MBBSZura Bio Limited
51
Stephen RaillardKodiak Sciences
N/A
Sue NaimAlx Oncology Holdings
N/A
Pamela DanagherTerns Pharmaceuticals
N/A
Alan FreidmanTranscode Therapeutics
N/A
RN MBATranscode Therapeutics
N/A
Elly MDDay One Biopharmaceuticals
N/A
Calais PharmTranscode Therapeutics
65
Ramiro MDEyepoint Pharmaceuticals
41
John StubenrauchDay One Biopharmaceuticals
N/A
Cheryl MadsenViracta Therapeutics
N/A
Robert McRaeViracta Therapeutics
N/A
Michael MBAAnnexon
53
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts. Minerva Neuroscie operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people. Minerva Neurosciences (NERV) is traded on NASDAQ Exchange in USA. It is located in 1500 District Avenue, Burlington, MA, United States, 01803 and employs 9 people. Minerva Neurosciences is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Return On Equity-6.75
Return On Asset-0.29

Minerva Neurosciences Leadership Team

Elected by the shareholders, the Minerva Neurosciences' board of directors comprises two types of representatives: Minerva Neurosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Minerva. The board's role is to monitor Minerva Neurosciences' management team and ensure that shareholders' interests are well served. Minerva Neurosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Minerva Neurosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
CPA CPA, CFO VP
Ramana Kuchibhatla, Senior Development
MBA FCMA, President
Remy Luthringer, Executive Vice President and Head of Research & Development (R&D)
FCMA FCMA, President
William Boni, Vice Communications
Joseph Reilly, COO and Sr. VP
Frederick CPA, CFO VP
Pr MD, Chief Officer

Minerva Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Minerva Neurosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-6.75
Return On Asset-0.29
Current Valuation(10.86 M)
Shares Outstanding6.99 M
Shares Owned By Insiders22.26 %
Shares Owned By Institutions30.47 %
Number Of Shares Shorted7.08 K
Price To Earning69.58 X
Price To Book2.68 X
Price To Sales1.87 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY